Cytopia begins Phase II
Thursday, 04 September, 2008
Cytopia [ASX: CYT] has commenced enrolment for its Phase 1b/II study of CYT997 for brain cancer.
CYT997 is a vascular disrupting agent being tested in patients with the aggressive brain cancer glioblastoma multiforme.
Around 30 patients will be involved in the study, which will be conducted at a number of clinical centres in Australia and overseas. CYT997 will be used in combination with two other marketed anticancer agents.
Glioblastomas often resurface even after surgical resection or radiation therapy, but are highly vascular and dependent on their own abnormal blood supply for growth. CYT997 is aimed at disrupting this supply.
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
Personalised brain stimulation helps treat those with depression
By tailoring transcranial magnetic stimulation to each person's unique brain structure,...
